Three major classes of opioid receptors, mu, delta and kappa, have been defined based on differences in their pharmacology, physiology and tissue distribution. When stimulated in vivo the opioid receptors activate a variety of intracellular reactions that effect calcium channels, potassium channels and adenylyl cyclase activity resulting in many of the classical effects of opiate intoxication including euphoria, analgesia and physical dependence. The molecular characterization of the opioid receptors was slow until the recent expression cloning of a mouse delta opioid receptor was reported. Based on this sequence we and others developed cloning strategies that led to the isolation of both kappa and mu opioid receptor cDNAs. The ability to express each of the opioid receptors in tissue culture permits their detailed pharmacological and physiological study. In a previous application we proposed that R21, a novel receptor we had cloned, encoded an opioid receptor based on the conservation of key amino acids and its overall homology with a mouse delta opioid receptor. Having demonstrated that R21 encodes a rat kappa opioid receptor, we are now ready to proceed with the molecular studies of this receptor. In particular we propose to extend out physiological studies to include the coupling of human and rat kappa opioid receptors to calcium and potassium channels. At the anatomical level as a first step towards evaluating the effects of chronic opiate use on kappa receptor expression we will begin to characterize its distribution in human brain material. An immunomodulatory role for opioids has been demonstrated and recently we obtained evidence that kappa opioid receptor mRNA is expressed in a mouse thymoma cell line. This provides us with an excellent opportunity to explore the effects of opioid exposure on cells of the immune system. To better understand how kappa opioid receptor expression is controlled we will characterize both the human and rat genes and in addition will attempt to identify markers that can be used in genetic linkage and association studies. Eventually the mouse kappa opioid receptor gene will be targeted and knocked out. These animals will be a valuable model system in which to evaluate the kappa receptor's role in processes ranging from synaptic transmission to behavior. Finally, we have cloned a receptor whose sequence and anatomical distribution suggest that it is a member of the opioid receptor gene family. We propose to continue the characterization of this interesting receptor using DNA sequence analysis, in vitro mutagenesis and expression studies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA008562-04
Application #
2013171
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Program Officer
Pollock, Jonathan D
Project Start
1993-12-10
Project End
2000-12-31
Budget Start
1997-02-01
Budget End
1997-12-31
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
Organized Research Units
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Grandy, David K (2007) Trace amine-associated receptor 1-Family archetype or iconoclast? Pharmacol Ther 116:355-90
Allen, R G; Peng, B; Pellegrino, M J et al. (2001) Altered processing of pro-orphanin FQ/nociceptin and pro-opiomelanocortin-derived peptides in the brains of mice expressing defective prohormone convertase 2. J Neurosci 21:5864-70
Allen, C N; Jiang, Z G; Teshima, K et al. (1999) Orphanin-FQ/nociceptin (OFQ/N) modulates the activity of suprachiasmatic nucleus neurons. J Neurosci 19:2152-60
Slugg, R M; Ronnekleiv, O K; Grandy, D K et al. (1999) Activation of an inwardly rectifying K+ conductance by orphanin-FQ/nociceptin in vasopressin-containing neurons. Neuroendocrinology 69:385-96
Tian, J H; Zhang, W; Fang, Y et al. (1998) Endogenous orphanin FQ: evidence for a role in the modulation of electroacupuncture analgesia and the development of tolerance to analgesia produced by morphine and electroacupuncture. Br J Pharmacol 124:21-6
Wagner, E J; Ronnekleiv, O K; Grandy, D K et al. (1998) The peptide orphanin FQ inhibits beta-endorphin neurons and neurosecretory cells in the hypothalamic arcuate nucleus by activating an inwardly-rectifying K+ conductance. Neuroendocrinology 67:73-82
Quigley, D I; McDougall, J; Darland, T et al. (1998) Orphanin FQ is the major OFQ1-17-containing peptide produced in the rodent and monkey hypothalamus. Peptides 19:133-9
Morgan, M M; Grisel, J E; Robbins, C S et al. (1997) Antinociception mediated by the periaqueductal gray is attenuated by orphanin FQ. Neuroreport 8:3431-4
Heinricher, M M; McGaraughty, S; Grandy, D K (1997) Circuitry underlying antiopioid actions of orphanin FQ in the rostral ventromedial medulla. J Neurophysiol 78:3351-8
Zhang, G; Murray, T F; Grandy, D K (1997) Orphanin FQ has an inhibitory effect on the guinea pig ileum and the mouse vas deferens. Brain Res 772:102-6

Showing the most recent 10 out of 16 publications